<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01320696</url>
  </required_header>
  <id_info>
    <org_study_id>831001</org_study_id>
    <nct_id>NCT01320696</nct_id>
  </id_info>
  <brief_title>Reverse Genetic H9N2 Influenza Vaccine Study in Adults</brief_title>
  <official_title>A Randomized, Double Blind, Multi-center, Phase 1/2 Study to Assess Safety and Immunogenicity of Five Dose Levels of a Reverse Genetic (RG) Reassortant H9N2 Pandemic Influenza Vaccine in Healthy Subjects Aged 18 to 49 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ology Bioservices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ology Bioservices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to identify the optimal dose level of a reverse genetic (RG)&#xD;
      reassortant H9N2 pandemic influenza vaccine for further product development.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with a hemagglutination inhibition (HI) antibody response to the vaccine strain (A/H9N2/chicken/Hong Kong/G9/97) associated with seroconversion 21 days after the second vaccination</measure>
    <time_frame>21 days after 2nd vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects achieving an HI antibody titer &gt;= 1:40 21 days after the second vaccination</measure>
    <time_frame>21 days after 2nd vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and severity of injection site and systemic reactions within 7 days after the first and second vaccination</measure>
    <time_frame>7 days after 1st and 2nd vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects achieving an HI antibody titer &gt;= 1:40 21 days after the first vaccination</measure>
    <time_frame>21 days after 1st vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with antibody response associated with protection 21 days after the first and second vaccination defined as microneutralization (MN) titer &gt;= 1:20</measure>
    <time_frame>21 days after 1st and 2nd vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with antibody response associated with protection 21 days after the first and second vaccination defined as Single Radial Hemolysis (SRH) area &gt;= 25 mm2</measure>
    <time_frame>21 days after 1st and 2nd vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody response 21 days after the first and second vaccination measured by HI, MN and SRH assays</measure>
    <time_frame>21 days after 1st and 2nd vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fold increase of antibody response 21 days after the first and second vaccination as compared to baseline measured by HI, MN and SRH assays</measure>
    <time_frame>21 days after 1st and 2nd vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with seroconversion (as defined for the primary immunogenicity endpoint) measured by HI assay 21 days after the first vaccination as compared to baseline</measure>
    <time_frame>21 days after 1st vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with seroconversion defined as a minimum fourfold increase in titer measured by MN assay 21 days after the first and second vaccination as compared to baseline</measure>
    <time_frame>21 days after 1st and 2nd vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with seroconversion as measured by SRH assay 21 days after the first and second vaccination</measure>
    <time_frame>21 days after 1st and 2nd vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with antibody response associated with protection 180 days after the first vaccination as measured by HI, MN and SRH assays</measure>
    <time_frame>180 days after 1st vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody response 180 days after the first vaccination measured by HI, MN and SRH assays</measure>
    <time_frame>180 days after 1st vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fold increase of antibody response 180 days after the first vaccination as compared to baseline measured by HI, MN and SRH assays</measure>
    <time_frame>180 days after 1st vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with fever, malaise and shivering with onset within 7 days after the first and second vaccination</measure>
    <time_frame>7 days after 1st and 2nd vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events (AEs) observed during the entire study period</measure>
    <time_frame>Entire study period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">275</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 subjects will be randomized 1:1:1:1:1 to 5 dose groups (10 subjects per treatment group) to receive 2 intramuscular injections of RG reassortant A/H9N2 influenza vaccine on Day 1 and Day 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After a safety data review of the first 50 subjects, a further 225 subjects will be randomized 1:1:1:1:1 to 5 dose groups and will receive 2 intramuscular injections of RG reassortant A/H9N2 influenza vaccine on Day 1 and Day 22</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine</intervention_name>
    <description>Two intramuscular vaccinations; 5 dose groups: 3.75 µg, 7.5 µg, 15 µg, 30 µg or 45 µg HA antigen (strain A/H9N2/chicken/Hong Kong/G9/97; non-adjuvanted formulation</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is 18 to 49 years of age, inclusive, on the day of screening&#xD;
&#xD;
          -  Subject has an understanding of the study and its procedures, agrees to its&#xD;
             provisions, and gives written informed consent prior to study entry&#xD;
&#xD;
          -  Subject is generally healthy, as determined by the investigator's clinical judgement&#xD;
             through collection of medical history and performance of a physical examination&#xD;
&#xD;
          -  Subject is physically and mentally capable of participating in the study as determined&#xD;
             by the investigator&#xD;
&#xD;
          -  Subject agrees to keep a daily record of symptoms for the duration of the study&#xD;
&#xD;
          -  If female of childbearing potential, subject presents with a negative urine pregnancy&#xD;
             test within 24 hours prior to first vaccination and agrees to employ adequate birth&#xD;
             control measures for the duration of the study. For the purposes of this study at&#xD;
             least one of the following types of US Food and Drug Administration (FDA) approved&#xD;
             birth control measures shall be applied through completion of the Day 181 study visit:&#xD;
&#xD;
               -  Hormonal types of birth control (such as implants or birth control pills) or an&#xD;
                  intrauterine device&#xD;
&#xD;
               -  A barrier type of birth control measure (i.e. condoms, diaphragms, cervical caps,&#xD;
                  etc.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has a history of exposure to H9N2 influenza virus or a history of vaccination&#xD;
             with an H9N2 influenza vaccine&#xD;
&#xD;
          -  Subject is at potential occupational risk of contracting H9N2 influenza infection&#xD;
             (e.g. poultry workers)&#xD;
&#xD;
          -  Subject currently suffers from or has a history of a significant (requiring&#xD;
             hospitalization or change in intervention in past 6 months)neurological,&#xD;
             cardiovascular, pulmonary (including asthma), hepatic, rheumatic, autoimmune,&#xD;
             hematological, metabolic or renal disorder such as but not limited to: multiple&#xD;
             sclerosis, lupus, Guillain-Barre syndrome as determined by the investigator&#xD;
&#xD;
          -  Subject has a body temperature of &gt;= 100.4 degrees Fahrenheit (&gt;= 38.0 degrees&#xD;
             Celsius) on the day of vaccination, by oral measurement. [NOTE: Subjects meeting this&#xD;
             exclusion criterion may be rescheduled for vaccination and study entry at a later date&#xD;
             provided: 1) body temperature measured orally has decreased to &lt; 100.4 degrees&#xD;
             Fahrenheit (&lt; 38.0 degrees Celsius); 2) all other inclusion/exclusion criteria are&#xD;
             met; 3) the rescheduled date is no more than 14 days past the initial screening&#xD;
             assessments and date; and 4) the study site is still enrolling subjects and&#xD;
             randomization is not closed]&#xD;
&#xD;
          -  Subject has a Body Mass Index (BMI) &gt;= 35&#xD;
&#xD;
          -  Subject has hypertension at screening that is graded as greater than Stage 1 (defined&#xD;
             as a systolic pressure &gt; 159 or diastolic pressure &gt; 99 while seated and at rest&#xD;
             (measurement shall be repeated twice before subject is excluded)&#xD;
&#xD;
          -  Subject has clinically significant abnormal laboratory values at screening as&#xD;
             determined by the investigator&#xD;
&#xD;
          -  Subject tests positive for Human Immunodeficiency Virus (HIV), Hepatitis B surface&#xD;
             Antigen (HBsAgs) or Hepatitis C Virus (HCV)&#xD;
&#xD;
          -  Subject has any medically diagnosed or suspected immune deficient condition based on&#xD;
             medical history and physical examination as determined by the investigator&#xD;
&#xD;
          -  Subject has an immune compromising condition or disease, or is currently undergoing a&#xD;
             form of treatment or was undergoing a form of treatment within 30 days prior to study&#xD;
             entry that can be expected to influence immune response. Such treatment includes, but&#xD;
             is not limited to, systemic or high dose inhaled (&gt; 800 μg/day of beclomethasone&#xD;
             dipropionate or equivalent) corticosteroids, radiation treatment or other&#xD;
             immunosuppressive or cytotoxic drugs (use of inhaled and nasal steroids will be&#xD;
             permitted)&#xD;
&#xD;
          -  Subject has a history of severe (required immediate medical life threatening treatment&#xD;
             and/or hospitalization) allergic reactions or anaphylaxis as determined by the&#xD;
             investigator&#xD;
&#xD;
          -  Subject has a rash, dermatologic condition or tattoos which may interfere with&#xD;
             injection site reaction rating as determined by the investigator&#xD;
&#xD;
          -  Subject has received any blood products (e.g. blood transfusion or immunoglobulins)&#xD;
             within 90 days prior to study entry&#xD;
&#xD;
          -  Subject has donated one or more units of blood (approximately 450 mL) or plasma within&#xD;
             30 days prior to study entry&#xD;
&#xD;
          -  Subject has received any live vaccine within 4 weeks or an inactivated vaccine or a&#xD;
             subunit vaccine within 2 weeks prior to vaccination in this study&#xD;
&#xD;
          -  Subject has a functional or surgical asplenia&#xD;
&#xD;
          -  Subject has a positive urine drug screen (unless the subject is currently prescribed&#xD;
             the drug detected by a licensed health care provider and the continued administration&#xD;
             of the drug would not otherwise exclude the subject from participation)&#xD;
&#xD;
          -  Subject has a known or suspected problem with alcohol or drug abuse as determined by&#xD;
             the investigator&#xD;
&#xD;
          -  Subject is currently enrolled or has participated in another clinical study involving&#xD;
             an investigational products (IP) or device within 30 days prior to study enrollment or&#xD;
             is scheduled to participate in another clinical study involving an IP or device during&#xD;
             the course of this study&#xD;
&#xD;
          -  Subject is a member of the team conducting this study or is in a dependent&#xD;
             relationship with one of the study team members. Dependent relationships include close&#xD;
             relatives (i.e. children, partner/spouse, siblings, parents) as well as employees of&#xD;
             the investigator or site personnel conducting the study&#xD;
&#xD;
          -  If female, subject is pregnant or lactating at the time of study enrollment&#xD;
&#xD;
          -  Any condition that in the opinion of the investigator would interfere with evaluation&#xD;
             of the vaccine or interpretation of study results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Izay, MD</last_name>
    <role>Study Director</role>
    <affiliation>Baxter Innovations GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Accelovance</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accelovance</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accelovance</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accelovance</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accelovance</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>March 21, 2011</study_first_submitted>
  <study_first_submitted_qc>March 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2011</study_first_posted>
  <last_update_submitted>October 5, 2015</last_update_submitted>
  <last_update_submitted_qc>October 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

